Chromene induces apoptosis via caspase-3 activation in human leukemia HL-60 cells. 2011

Soo-Jin Heo, and Kil-Nam Kim, and Weon-Jong Yoon, and Chulhong Oh, and Young-Ung Choi, and Abu Affan, and Yeon-Ju Lee, and Hyi-Seung Lee, and Do-Hyung Kang
Marine Living Resources Research Department, Korea Ocean Research and Development Institute, Ansan 426-744, Republic of Korea.

In this study, the potent anti-tumor effects of brown algae on human leukemia HL-60 cells were investigated. The Sargassum siliquastrum extract among the 14 species of brown algae exhibited profound growth inhibitory effect on HL-60 cells in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, therefore, S. siliquastrum was selected for use in further experiments. The highest inhibitory activity of S. siliquastrum on HL-60 cells was detected in the chloroform fraction, and the active compound was identified as a kind of chromene, sargachromanol E (SE). SE treatment showed significant growth inhibitory effects on HL-60 cells in a dose-dependent manner by inducing apoptosis, as evidenced by the formation of apoptotic bodies, fragmented DNA ladder, and the accumulation of DNA in the sub-G(1) phase of cell cycle. SE induced apoptosis was accompanied by downregulation of Bcl-xL, upregulation of Bax, activation of caspase-3, and cleavage of poly (ADP-ribose) polymerase (PARP). Moreover, z-DEVD-fmk, a caspase-3 inhibitor, significantly inhibited cell cytotoxicity, apoptotic characteristics such as apoptotic bodies, sub-G(1) DNA content, and cleavage of PARP induced by SE. These results suggest that SE exerts its growth inhibitory effects on HL-60 cells through caspase-3-mediated induction of apoptosis. Therefore, SE offers promising chemotherapeuric potential to prevent cancers such as human leukemia.

UI MeSH Term Description Entries
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001578 Benzopyrans Compounds with a core of fused benzo-pyran rings. Benzopyran,Chromene,Chromenes
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D053148 Caspase 3 A short pro-domain caspase that plays an effector role in APOPTOSIS. It is activated by INITIATOR CASPASES such as CASPASE 9. Isoforms of this protein exist due to multiple alternative splicing of its MESSENGER RNA. CASP3,Apopain,Caspase-3,Pro-Caspase-3,Procaspase-3,Pro Caspase 3,Procaspase 3
D018922 HL-60 Cells A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8) HL60 Cells,Cell, HL60,Cells, HL60,HL 60 Cells,HL-60 Cell,HL60 Cell

Related Publications

Soo-Jin Heo, and Kil-Nam Kim, and Weon-Jong Yoon, and Chulhong Oh, and Young-Ung Choi, and Abu Affan, and Yeon-Ju Lee, and Hyi-Seung Lee, and Do-Hyung Kang
July 2000, Archives of toxicology,
Soo-Jin Heo, and Kil-Nam Kim, and Weon-Jong Yoon, and Chulhong Oh, and Young-Ung Choi, and Abu Affan, and Yeon-Ju Lee, and Hyi-Seung Lee, and Do-Hyung Kang
January 2002, Toxicology,
Soo-Jin Heo, and Kil-Nam Kim, and Weon-Jong Yoon, and Chulhong Oh, and Young-Ung Choi, and Abu Affan, and Yeon-Ju Lee, and Hyi-Seung Lee, and Do-Hyung Kang
January 2000, Cell biology and toxicology,
Soo-Jin Heo, and Kil-Nam Kim, and Weon-Jong Yoon, and Chulhong Oh, and Young-Ung Choi, and Abu Affan, and Yeon-Ju Lee, and Hyi-Seung Lee, and Do-Hyung Kang
April 2007, Chemico-biological interactions,
Soo-Jin Heo, and Kil-Nam Kim, and Weon-Jong Yoon, and Chulhong Oh, and Young-Ung Choi, and Abu Affan, and Yeon-Ju Lee, and Hyi-Seung Lee, and Do-Hyung Kang
October 2010, Journal of controlled release : official journal of the Controlled Release Society,
Soo-Jin Heo, and Kil-Nam Kim, and Weon-Jong Yoon, and Chulhong Oh, and Young-Ung Choi, and Abu Affan, and Yeon-Ju Lee, and Hyi-Seung Lee, and Do-Hyung Kang
December 1999, Cancer letters,
Soo-Jin Heo, and Kil-Nam Kim, and Weon-Jong Yoon, and Chulhong Oh, and Young-Ung Choi, and Abu Affan, and Yeon-Ju Lee, and Hyi-Seung Lee, and Do-Hyung Kang
October 1997, Cell death and differentiation,
Soo-Jin Heo, and Kil-Nam Kim, and Weon-Jong Yoon, and Chulhong Oh, and Young-Ung Choi, and Abu Affan, and Yeon-Ju Lee, and Hyi-Seung Lee, and Do-Hyung Kang
April 2001, Carcinogenesis,
Soo-Jin Heo, and Kil-Nam Kim, and Weon-Jong Yoon, and Chulhong Oh, and Young-Ung Choi, and Abu Affan, and Yeon-Ju Lee, and Hyi-Seung Lee, and Do-Hyung Kang
November 2001, Acta pharmacologica Sinica,
Soo-Jin Heo, and Kil-Nam Kim, and Weon-Jong Yoon, and Chulhong Oh, and Young-Ung Choi, and Abu Affan, and Yeon-Ju Lee, and Hyi-Seung Lee, and Do-Hyung Kang
January 1999, Journal of biochemical and molecular toxicology,
Copied contents to your clipboard!